AURX · Nuo Therapeutics, Inc.
$1.14
+0.04 (+3.64%)
At close · Aug 31
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products and the Private Label product to Smith+Nephew are insufficient to support our operations for the next 12 months from the date these financial statements are issued. As such, we believe that substantial doubt about our ability to continue as a going concern exists.”View the 10-Q filed Aug 14, 2026
Market Cap
$53.28M
Shares
48.43M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.31M
+142.7%
FY2025
Net Income
-$2.51M
-8.1%
FY2025
Gross Margin
66.94%
-10.9pp
FY2025
Operating Margin
-75.95%
+104.1pp
FY2025
Diluted EPS
-$0.03
-111.1%
FY2021
Operating Cash Flow
-$864.97K
+61.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.2M | $3.31M | $1.37M | $608.53K | $112.25K | $0 | $0 | $146.18K | $1.37M | $721.05K | $11.51M | $7.76M | $11.57M | $10.56M | $7.25M | $3.91M | |
| $1.87M | $1.1M | $302.84K | $126.09K | $19.21K | $0 | $0 | $114.61K | $162.99K | $1.09M | $7.97M | $6.77M | $8.45M | $3.91M | $2.73M | $1.61M | |
| $3.33M | $2.22M | $1.06M | $482.43K | $93.04K | $0 | $0 | $31.56K | $1.21M | -$370K | $3.54M | $991.19K | $3.12M | $6.65M | $4.52M | $2.3M | |
| — | 66.94% | 77.82% | 79.28% | 82.88% | — | — | 21.59% | 88.11% | -51.31% | 30.79% | 12.77% | 26.95% | 62.95% | 62.37% | 58.76% | |
| — | — | — | — | — | $0 | $0 | $181.19K | $576.19K | $1.33M | $2.55M | $4.04M | $3.8M | $3.39M | $98.15K | $415.63K | |
| — | — | — | — | — | $0 | $0 | $30.46K | $114.88K | $712.74K | $6.24M | $5.78M | — | — | — | — | |
| — | — | — | — | — | $90.67K | $378.06K | $789.12K | $2.02M | $3.82M | $9.02M | $9.88M | $6.79M | $5.59M | $2.95M | $2.64M | |
| $5.07M | $4.73M | $3.52M | $3.65M | $3.41M | $90.67K | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $852K | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $0 | $89.86K | $102.2K | $1.11M | $740.97K | $613.5K | $1.09M | $1.18M | $631.18K | $440.18K | |
| — | — | — | — | — | — | — | — | — | — | — | $695K | — | — | — | — | |
| $5.07M | $4.73M | $3.52M | $3.65M | $3.41M | $90.67K | $378.06K | $1M | $2.71M | $15.16M | $44.86M | $24.38M | $21.21M | $19.54M | $8.03M | $7.7M | |
| -$1.73M | -$2.52M | -$2.46M | -$3.17M | -$3.32M | -$90.67K | -$378.06K | -$969.2K | -$1.5M | -$15.53M | -$41.32M | -$23.39M | -$18.1M | -$12.89M | -$3.51M | -$5.4M | |
| — | -75.95% | -180.04% | -520.65% | -2958.21% | — | — | -663.03% | -109.78% | -2154.4% | -358.96% | -301.35% | -156.38% | -122.06% | -48.49% | -138.15% | |
| — | — | — | — | — | -$90.67K | -$378.06K | -$879.34K | -$1.4M | -$14.42M | -$40.58M | -$22.78M | -$17M | -$11.72M | -$2.88M | -$4.96M | |
| — | — | — | — | — | — | — | — | — | — | $28.34K | $45.43K | — | — | — | — | |
| -$279.16K | $5237 | $402 | $0 | $4523 | $0 | $0 | -$4237 | -$37.12K | $555.5K | -$11.58M | $4.53M | -$2.13M | -$6.89M | $21.8K | -$1.4M | |
| — | -$2.51M | -$2.32M | -$3.17M | -$3.17M | -$90.67K | -$90.87K | -$1.19M | -$1.54M | -$14.98M | -$52.9M | -$18.86M | -$20.23M | -$19.78M | -$3.49M | -$6.8M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | -$89.01K | $19.58K | $18.59K | $18K | $18K | $14K | |
| -$2.01M | -$2.51M | -$2.32M | -$3.17M | -$3.17M | -$90.67K | -$90.87K | -$1.19M | -$1.54M | -$14.98M | -$52.81M | -$18.88M | -$20.25M | -$19.8M | -$3.51M | -$6.82M | |
| — | -75.82% | -170.21% | -521.17% | -2825.6% | — | — | -817.43% | -112.49% | -2077.36% | -458.76% | -243.28% | -174.99% | -187.41% | -48.44% | -174.3% | |
| — | — | — | — | -$3.17M | -$886.26K | $7.71M | -$1.19M | -$1.54M | -$14.98M | — | -$18.88M | -$20.25M | -$19.81M | -$3.86M | -$9.04M | |
| USD/shares | -$0.04 | -$0.05 | -$0.05 | -$0.08 | -$0.08 | -$0.03 | $0.30 | -$0.05 | -$0.07 | -$1.02 | — | — | — | — | — | — |
| USD/shares | — | — | — | — | — | -$0.03 | $0.27 | -$0.05 | -$0.07 | -$1.02 | — | — | — | — | — | — |
| shares | — | 47.31M | 45.42M | 42.08M | 40M | 30.3M | 25.69M | 23.72M | 23.28M | 14.65M | 125.95M | 120.52M | 103.62M | 81.86M | 50.67M | — |
| shares | — | — | — | — | — | 30.3M | 27.31M | 23.72M | 23.28M | 14.65M | 125.95M | 120.52M | 103.62M | 81.86M | 50.67M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.91×
EV/EBIT
—
Peer median 12.89×
P/E (TTM)
—
Peer median 5.81×
Peer medians compare against the 266 similar-size Biotechnology companies (of 497 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $3,088,509 | $1,365,173 | $608,525 | $112,250 | $0 | $0 | $146,177 |
| Aurix and Private Label Kits | $1,225,000 | — | — | — | — | — | — |
| License | $225,000 | $0 | — | — | — | — | — |
| Aurix and Private Label Centrifuge Devices | $77,000 | — | — | — | — | — | — |